Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK139 in Chronic Spontaneous Urticaria
NCT07875426Phase 2Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- Oct 2026
- Primary completion
- Jan 2029
01
Overview
A Phase 2 trial of AK139 in chronic spontaneous urticaria (CSU), sponsored by Akeso, Inc.. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
AK139
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT07875426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07875426.